# Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

> **NCT05383482** · PHASE1,PHASE2 · COMPLETED · sponsor: **Laekna Limited** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumor
- NSCLC
- Cervical Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gastric and Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Afuresertib
- **DRUG:** Nab paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT05383482
- **Lead sponsor:** Laekna Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2024-06-25
- **Final completion:** 2024-07-18
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05383482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05383482, "Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05383482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*